{"id":"W4391430347","doi":"10.1016/j.ejca.2024.113585","title":"Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma","year":2024,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Manchester Biomedical Research Centre; Array BioPharma; Ipsen; Genentech; Deutsche Krebshilfe; Eisai; National Institute for Health and Care Research; Italfarmaco; Seagen; Sanofi Pasteur; Galecto; SkylineDx; Cancer Research UK; NeraCare; Sun Pharma; Regeneron Pharmaceuticals; Sanofi; Pfizer; InflaRx; Les Laboratories Pierre Fabre; Daiichi Sankyo Europe; Bayer; Bristol-Myers Squibb; AstraZeneca; Amgen","keywords":"Medicine; Pembrolizumab; Placebo; Internal medicine; Hazard ratio; Adverse effect; Incidence (geometry); Melanoma; Gastroenterology; Clinical trial; Surgery; Oncology; Cancer; Immunotherapy; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00159816,0.0006728487,0.001142155,0.0002148148,0.0002130648,0.0009528301,0.0004233715,0.0006146394,0.001465284],"category_scores_gemma":[0.001976831,0.0002495181,0.001008849,0.0002401013,0.0004466026,0.000681476,0.0002758014,0.001329329,0.0002290712],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005001737,"about_ca_system_score_gemma":0.0004466537,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004145032,"about_ca_topic_score_gemma":0.001134556,"domain_scores_codex":[0.9995377,0.0002578696,0.00002511259,0.00007287959,0.00004439297,0.00006203039],"domain_scores_gemma":[0.9989785,0.0004266085,0.0002361709,0.00007203658,0.00004128495,0.0002454096],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7692802,0.003013054,0.1228626,0.0004811624,0.003485792,0.0001711452,0.0001387675,0.00299477,0.01430093,0.0002697839,0.002026597,0.08097522],"study_design_scores_gemma":[0.1563594,0.1454619,0.6671791,0.0002087856,0.008205104,0.0005906367,0.0002905072,0.009538282,0.005592184,0.001349545,0.005088709,0.0001356812],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963199,0.002329155,0.00008427945,0.0001901503,0.00008834896,0.00004404086,0.0002304025,0.000008993905,0.0007047287],"genre_scores_gemma":[0.9984388,0.0004157357,0.0001328423,0.0001340808,0.00010794,0.00003924743,0.0003733911,0.000003642783,0.0003543547],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00159816,"threshold_uncertainty_score":0.008451998,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01244482816295829,"score_gpt":0.2935422822969203,"score_spread":0.281097454133962,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}